Johnson & Johnson sees $125 M of insider sales, ratio hits 0.00x

Over the last year Johnson & Johnson (JNJ) recorded a single insider purchase of 257,688 shares worth $257,688, contrasted with 38 separate sales totaling $125,079,154. The resulting buy‑sell ratio of 0.00x sits well below the 0.2x benchmark that signals heavy insider selling, even after accounting for routine compensation‑related trades. Ten distinct insiders were involved, but the concentration of value in C‑suite transactions is striking. Chief Executive Joaquin Duato sold three blocks of shares—125,824 shares for $22.55 million on August 22 2025, 51,218 shares for $11.32 million and 48,782 shares for $10.80 million on January 26 2026—collectively representing $44.67 million, or 35.6% of total insider sales. Chief Financial Officer Joseph J. Wolk disposed of 33,386 shares for $8.10 million on February 17 2026, adding $24.74 million in CFO‑level sales. Senior vice‑president and executive vice‑president Jennifer L. Taubert sold 56,471 shares for $10.04 million on September 4 2025, contributing $53.94 million of the 14 VP/SVP/EVP sales recorded. These three senior‑level groups accounted for $119.35 million, or 95% of the total sell value.

The timing of the sales underscores a clustering effect. Between January 1 2026 and February 28 2026, seven transactions by the CEO, CFO and a senior VP amassed $80.48 million, a cluster that exceeds the three‑insider‑in‑30‑days signal often interpreted as coordinated activity. By contrast, there was no comparable buying cluster; the lone director purchase in November 2025 was modest and did not offset the broader sell pressure.

Market context tempers the raw numbers. JNJ’s share price sits at $228.98, up 1.00% on the day and delivering a 10.6% gain year‑to‑date. The stock trades at 78% of its 52‑week high and registers an RSI of 52, indicating neutral momentum rather than overbought conditions. While a rising price can motivate insiders to lock in gains, the scale of the C‑suite disposals—especially the CEO’s three‑transaction burst—suggests a level of confidence that diverges from the broader shareholder base.

Routine explanations such as tax planning or diversification cannot fully account for the magnitude and concentration of these sales. Historically, insider selling that exceeds $10 million per executive and clusters within a short window has preceded periods of heightened volatility or strategic pivots. Investors should monitor upcoming earnings releases and any disclosed rationale in Form 4 filings for clues about whether the sales reflect personal liquidity needs or a reassessment of the company’s growth trajectory.

In sum, Johnson & Johnson’s insider activity profile over the past twelve months is dominated by large, coordinated sales from top executives, a pattern that stands out against a backdrop of modest price appreciation and neutral technical indicators. The data points to a need for heightened scrutiny rather than a simple attribution to routine compensation events.